Business Context and Reporting Period
This Form 8-K Current Report was filed by Aixcrypto Holdings, Inc. on May 21, 2026. The filing primarily addresses significant changes in executive leadership, board composition, and a strategic decision to discontinue a legacy business segment.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The document focuses on corporate governance and strategic restructuring rather than financial results.
Material Changes
Executive and Board Resignations
- Kevin Richardson II: Resigned as Co-Chief Executive Officer and Director, effective immediately.
- Koti Meka: Resigned as Director (effective immediately) and Chief Financial Officer (effective June 20, 2026).
- Campbell Becher: Resigned as President, effective immediately.
- Note: The Company states these departures are not the result of any disagreement regarding operations, policies, or practices.
Executive and Board Appointments
- Jie (Jay) Sheng: Appointed President and Chief Financial Officer (effective June 21, 2026). He ceases to be an independent director and Audit Committee member upon appointment.
- Jerry Wang: Appointed as a Director, effective immediately. He currently serves as Co-CEO and is the nephew of the CEO of the Company's majority shareholder.
- Chen Shi: Appointed as an Independent Director, effective immediately. He is expected to chair the Audit Committee.
Compensation for New Appointee
Mr. Sheng's compensation package includes:
- Annual base salary: $400,000.
- Discretionary annual performance bonus: Up to $200,000.
- Restricted Stock Units (RSUs): Grant date value of $312,000, vesting over four years.
- Performance Stock Units (PSUs): Value of $208,000, subject to milestones and Board approval.
Strategic Business Change
The Board approved the discontinuation and structured wind-down of the Company's legacy biotechnology business segment. The Company is currently evaluating the financial impact, including potential charges and asset impairments.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the wind-down of the biotechnology segment and the transition of executive leadership. Key risks and contingencies identified include:
- The ability to successfully execute the wind-down of the biotechnology segment.
- Unspecified costs and charges associated with the wind-down.
- Risks related to retaining key personnel during the executive transition.
- Uncertainty regarding the grant of equity awards, which depends on Board approval and share availability.
The Company expects to provide additional details on the financial impact of the wind-down in its next periodic report.
Investor Verification Checklist
- Verify the specific financial impact, including impairment charges and wind-down costs, in the next 10-Q or 10-K filing.
- Confirm the final vesting schedule and grant details for Mr. Sheng's equity awards once approved by the Board.
- Monitor the transition timeline for the CFO role between Mr. Meka's departure (June 20) and Mr. Sheng's start (June 21).
- Review the Company's updated capital structure and liquidity position following the cessation of the biotechnology segment.